Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00003633
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 67
- Registration Number
- NCT00040885
- Locations
- 🇺🇸
Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
🇺🇸St. Mary-Corwin Regional Medical Center, Pueblo, Colorado, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 600
- Registration Number
- NCT00003159
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
🇬🇧Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 21
- Registration Number
- NCT00030654
- Locations
- 🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
🇺🇸Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00045448
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Women With Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 446
- Registration Number
- NCT00047099
- Locations
- 🇩🇪
Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany
🇩🇪I. Frauenklinik und Hebammenschule der Ludwig-Maximillians Universitaet Muenchen, Munich, Germany
Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Introgen Therapeutics
- Registration Number
- NCT00044993
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT00030407
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00016185
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Nuvance Health
- Registration Number
- NCT00046826
- Locations
- 🇺🇸
Whittingham Cancer Center at Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸Carl and Dorothy Bennett Cancer Center at Stamford Hospital, Stamford, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.